Practice Management News

Despite vastly improved sustained virologic response rates with 12 weeks of newer therapies, researchers have continuously worked for shorter, still effective treatment windows, believing that a cure obtained in 4 or 6 weeks would lighten the load of adherence and cost placed on patients with hepatitis C virus.

In markets where the CE Mark is observed, Roche has launched the cobas DPX test, a real-time PCR duplex assay for detecting parvovirus B19 and hepatitis A virus in human plasma, according to a news release from the manufacturer.

Noninferiority trials appear to demonstrate near-complete reporting of designs and margins, but only a small proportion of these studies provide justification for choosing margins, according to researchers at Yale University.

Sofosbuvir-based treatment regimens were the most efficacious and cost-effective therapies in treating patients with hepatitis C virus genotype 1 and 3, according to newly published data in Annals of Internal Medicine.

Harvoni is cost-effective for most patients with hepatitis C virus infection, but additional resources and value-based patient prioritization are needed, according to newly published data in Annals of Internal Medicine.

Despite public perception to the contrary, the introduction of universal prescription drug coverage in Canada would not require significant tax increases, but instead could reduce the country’s total spending on prescription drugs, according to recent findings published in the Canadian Medical Association Journal.

The World Health Organization has issued guidelines for the first time for the treatment of chronic hepatitis B virus infection, according to a news release from the organization.

Unmet health care service and information needs, as well as emotional and psychological needs, were common among caregivers of patients with cancer, according to study results.

Bring your own device technology improves patient outcomes and saves money for hospitals by allowing physicians to use their own mobile devices to access, collect, share and store patient information within the palm of their hands, but with these advantages come cybersecurity risks.

The European Medicines Agency has approved a “2+1” immunization schedule for Hexyon, a pediatric vaccine that protects against multiple viruses, including hepatitis B virus infection, according to a press release.